Piper Sandler analyst Christopher Raymond reiterated a Buy rating on Cogent Biosciences (COGT - Research Report) on August 9 and set a price target of $22.00. The company's shares closed last Friday at $14.13.According to TipRanks, Raymond is a 4-star analyst with an average return of 4.0% and a 50.00% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Cogent Biosciences, and AlloVir.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cogent Biosciences with a $19.00 average price target, which is a 34.47% upside from current levels.
https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-cogent-biosciences-cogt?utm_source=advfn.com&utm_medium=referral
Cogent Biosciences (NASDAQ:COGT)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Cogent Biosciences Charts.
Cogent Biosciences (NASDAQ:COGT)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Cogent Biosciences Charts.